Stryker Corporation (NYSE:SYK) was upgraded by equities researchers at Robert W. Baird from a “neutral” rating to an “outperform” rating in a note issued to investors on Thursday. The firm currently has a $173.00 price objective on the medical technology company’s stock, up from their previous price objective of $161.00. Robert W. Baird’s price objective suggests a potential upside of 11.33% from the stock’s previous close.

SYK has been the topic of several other research reports. SunTrust Banks, Inc. restated a “buy” rating and issued a $161.00 target price on shares of Stryker Corporation in a report on Monday, October 2nd. Stifel Nicolaus boosted their target price on shares of Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a report on Friday, July 28th. Oppenheimer Holdings, Inc. set a $156.00 target price on shares of Stryker Corporation and gave the company a “hold” rating in a report on Monday, October 30th. Canaccord Genuity boosted their target price on shares of Stryker Corporation from $155.00 to $162.00 and gave the company a “buy” rating in a report on Friday, October 27th. Finally, BidaskClub lowered shares of Stryker Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Stryker Corporation has an average rating of “Hold” and an average price target of $152.10.

Stryker Corporation (SYK) opened at $155.40 on Thursday. The company has a market cap of $58,560.00, a price-to-earnings ratio of 24.72, a PEG ratio of 2.46 and a beta of 0.79. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. Stryker Corporation has a fifty-two week low of $108.29 and a fifty-two week high of $160.62.

Stryker Corporation (NYSE:SYK) last issued its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. Stryker Corporation’s revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.39 earnings per share. research analysts forecast that Stryker Corporation will post 6.47 EPS for the current year.

WARNING: “Stryker Corporation (SYK) Rating Increased to Outperform at Robert W. Baird” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/11/18/stryker-corporation-syk-rating-increased-to-outperform-at-robert-w-baird.html.

In other news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares of the company’s stock, valued at $12,925,375.38. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.40% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC purchased a new position in Stryker Corporation during the second quarter worth about $111,000. Motco boosted its holdings in Stryker Corporation by 50.7% during the second quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 278 shares during the last quarter. Bollard Group LLC boosted its holdings in Stryker Corporation by 0.4% during the second quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 3 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its holdings in Stryker Corporation by 47.8% during the third quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 325 shares during the last quarter. Finally, Bruderman Asset Management LLC purchased a new position in Stryker Corporation during the second quarter worth about $150,000. Institutional investors and hedge funds own 74.15% of the company’s stock.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.